{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:31:36Z","timestamp":1760887896532},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"DOI":"10.1093\/ndt\/gfl289","type":"journal-article","created":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T20:28:45Z","timestamp":1149884925000},"page":"2065-2068","source":"Crossref","is-referenced-by-count":18,"title":["Phosphate binders and management of hyperphosphataemia in end-stage renal disease"],"prefix":"10.1093","volume":"21","author":[{"given":"Vincenzo","family":"Savica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo A.","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Monardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Bellinghieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,6,9]]},"reference":[{"key":"key\n\t\t\t\t20171012174017_BIB1","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant2000; 15: 1014\u20131021","DOI":"10.1093\/ndt\/15.7.1014"},{"key":"key\n\t\t\t\t20171012174017_BIB2","doi-asserted-by":"crossref","unstructured":"Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med2000; 342: 1478\u20131483","DOI":"10.1056\/NEJM200005183422003"},{"key":"key\n\t\t\t\t20171012174017_BIB3","doi-asserted-by":"crossref","unstructured":"Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis2000; 35: 1226\u20131237","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"key\n\t\t\t\t20171012174017_BIB4","doi-asserted-by":"crossref","unstructured":"Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant2004; 19 [Suppl 5]: V59\u2013V66","DOI":"10.1093\/ndt\/gfh1058"},{"key":"key\n\t\t\t\t20171012174017_BIB5","doi-asserted-by":"crossref","unstructured":"Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist. Kidney Int2004; 66: 1315\u20131333","DOI":"10.1111\/j.1523-1755.2004.00895.x"},{"key":"key\n\t\t\t\t20171012174017_BIB6","doi-asserted-by":"crossref","unstructured":"Amann K, Tornig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int2003; 63: 1296\u20131301","DOI":"10.1046\/j.1523-1755.2003.00864.x"},{"key":"key\n\t\t\t\t20171012174017_BIB7","doi-asserted-by":"crossref","unstructured":"Eknoyan G, Levin A, Levin NW. National Kidney Foundation. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis2003; 42 [Suppl 3]: S1\u2013S201","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"key\n\t\t\t\t20171012174017_BIB8","doi-asserted-by":"crossref","unstructured":"Kopple JD. National Kidney Foundation K\/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis2001; 37 [Suppl 2]: S66\u2013S70","DOI":"10.1053\/ajkd.2001.20748"},{"key":"key\n\t\t\t\t20171012174017_BIB9","doi-asserted-by":"crossref","unstructured":"Mallick NP, Gokal R. Haemodialysis. Lancet1999; 353: 737\u2013742","DOI":"10.1016\/S0140-6736(97)09411-7"},{"key":"key\n\t\t\t\t20171012174017_BIB10","doi-asserted-by":"crossref","unstructured":"Alfrey AC, Legendre GR, Kaehny WD. Dialysis encephalopathy syndrome: possible aluminum intoxications. N Engl J Med1976; 294: 184\u2013188","DOI":"10.1056\/NEJM197601222940402"},{"key":"key\n\t\t\t\t20171012174017_BIB11","doi-asserted-by":"crossref","unstructured":"Hewitt CD, Savory J, Wills MR. Aspects of aluminum toxicity. Clin Lab Med1990; 10: 403\u2013422","DOI":"10.1016\/S0272-2712(18)30576-6"},{"key":"key\n\t\t\t\t20171012174017_BIB12","doi-asserted-by":"crossref","unstructured":"Goodman WG. Bone disease and aluminum: pathogenic considerations. Am J Kidney Dis1985; 6: 330\u2013335","DOI":"10.1016\/S0272-6386(85)80089-5"},{"key":"key\n\t\t\t\t20171012174017_BIB13","doi-asserted-by":"crossref","unstructured":"Ritz E. Managing mineral balance in end-stage renal disease. Nephrol Dial Transplant2004; 19 [Suppl 1]: S1\u2013S3","DOI":"10.1093\/ndt\/gfh1000"},{"key":"key\n\t\t\t\t20171012174017_BIB14","doi-asserted-by":"crossref","unstructured":"Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med1986; 315: 157\u2013161","DOI":"10.1056\/NEJM198607173150304"},{"key":"key\n\t\t\t\t20171012174017_BIB15","doi-asserted-by":"crossref","unstructured":"Emmett M, Sirmon M, Kirkpatrick W, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis1991; 5: 544\u2013550","DOI":"10.1016\/S0272-6386(12)80496-3"},{"key":"key\n\t\t\t\t20171012174017_BIB16","doi-asserted-by":"crossref","unstructured":"Chertow GM, Dillon MA, Amin N, Burke SK. Sevelamer with and without calcium and vitamin D: observations from a longterm open-label clinical trial. J Ren Nutr2000; 10: 125\u2013132","DOI":"10.1053\/jren.2000.7410"},{"key":"key\n\t\t\t\t20171012174017_BIB17","doi-asserted-by":"crossref","unstructured":"Burke SK, Slatopolsky E, Goldberg DI. Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant1997; 12: 1640\u20131644","DOI":"10.1093\/ndt\/12.8.1640"},{"key":"key\n\t\t\t\t20171012174017_BIB18","doi-asserted-by":"crossref","unstructured":"Slatopolsky E, Burke SK, Dillon MA. and The Renagel Study Group. Renagel, a nonabsorbed calcium- and aluminum free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int1999; 55: 299\u2013307","DOI":"10.1046\/j.1523-1755.1999.00240.x"},{"key":"key\n\t\t\t\t20171012174017_BIB19","doi-asserted-by":"crossref","unstructured":"Goldberg DI, Dillon MA, Slatopolsky E, et al. Effect of Renagel, a non absorbed, calcium and aluminum free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end stage renal disease patients. Nephrol Dial Transplant1998; 13: 2303\u20132310","DOI":"10.1093\/ndt\/13.9.2303"},{"key":"key\n\t\t\t\t20171012174017_BIB20","doi-asserted-by":"crossref","unstructured":"Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrocloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis1999; 33: 694\u2013701","DOI":"10.1016\/S0272-6386(99)70221-0"},{"key":"key\n\t\t\t\t20171012174017_BIB21","doi-asserted-by":"crossref","unstructured":"Chertow GM, Burke SK, Dillon MA, Slatopolsky E. For the Renagel Study Group. Long-term effects of sevelamer hydrocloride on the calcium \u00d7 phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant1999; 14: 2907\u20132914","DOI":"10.1093\/ndt\/14.12.2907"},{"key":"key\n\t\t\t\t20171012174017_BIB22","doi-asserted-by":"crossref","unstructured":"Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int2004; 90 [Suppl]: S25\u2013S32","DOI":"10.1111\/j.1523-1755.2004.09005.x"},{"key":"key\n\t\t\t\t20171012174017_BIB23","doi-asserted-by":"crossref","unstructured":"Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int2002; 62: 245\u2013252","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"key\n\t\t\t\t20171012174017_BIB24","doi-asserted-by":"crossref","unstructured":"Nagano N, Miyata S, Abe M, et al. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol Dial Transplant2006; 21: 634\u2013643","DOI":"10.1093\/ndt\/gfi137"},{"key":"key\n\t\t\t\t20171012174017_BIB25","unstructured":"Raggi P. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin Nephrol2000; 54: 325\u2013333"},{"key":"key\n\t\t\t\t20171012174017_BIB26","doi-asserted-by":"crossref","unstructured":"Raggi P. Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol Dial Transplant2002; 17: 332\u2013335","DOI":"10.1093\/ndt\/17.2.332"},{"key":"key\n\t\t\t\t20171012174017_BIB27","doi-asserted-by":"crossref","unstructured":"Behets GJ, Verberckmoes SC, D\u2019Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens2004; 13: 403\u2013409","DOI":"10.1097\/01.mnh.0000133973.86816.e9"},{"key":"key\n\t\t\t\t20171012174017_BIB28","unstructured":"Locatelli F, D\u2019Amico M, Pontoriero G. Lanthanum carbonate. Drugs2003; 6: 688\u2013695"},{"key":"key\n\t\t\t\t20171012174017_BIB29","doi-asserted-by":"crossref","unstructured":"Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis2003; 42: 96\u2013107","DOI":"10.1016\/S0272-6386(03)00554-7"},{"key":"key\n\t\t\t\t20171012174017_BIB30","doi-asserted-by":"crossref","unstructured":"Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant2004; 19: 1902\u20131906","DOI":"10.1093\/ndt\/gfh282"},{"key":"key\n\t\t\t\t20171012174017_BIB31","doi-asserted-by":"crossref","unstructured":"Finn WF. SPD 405\u2013307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol2006; 65: 202","DOI":"10.5414\/CNP65191"},{"key":"key\n\t\t\t\t20171012174017_BIB32","unstructured":"Damment SJP, Gill M. The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol), a new non-aluminum, non-calcium phosphate binder [Abstract]. J Am Soc Nephrol2003; 14: 204A"},{"key":"key\n\t\t\t\t20171012174017_BIB33","doi-asserted-by":"crossref","unstructured":"Lacour B, Lucas A, Auchere D, Ruellan N, De Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int2005; 67: 1062\u20131069","DOI":"10.1111\/j.1523-1755.2005.00171.x"},{"key":"key\n\t\t\t\t20171012174017_BIB34","doi-asserted-by":"crossref","unstructured":"Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int2005; 68: 2809\u20132813","DOI":"10.1111\/j.1523-1755.2005.00753.x"},{"key":"key\n\t\t\t\t20171012174017_BIB35","doi-asserted-by":"crossref","unstructured":"Behets GJ, Dams G, Damment S, et al. Does the phosphate binder lanthanum carbonate affect bone in chronic renal failure rats? J Am Soc Nephrol2004; 15: 2219\u20132228","DOI":"10.1097\/01.ASN.0000133022.32912.95"},{"key":"key\n\t\t\t\t20171012174017_BIB36","doi-asserted-by":"crossref","unstructured":"D\u2019Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int2003; 63 [Suppl]: S73\u2013S78","DOI":"10.1046\/j.1523-1755.63.s85.18.x"},{"key":"key\n\t\t\t\t20171012174017_BIB37","doi-asserted-by":"crossref","unstructured":"Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol2005; 63: 138\u2013145","DOI":"10.5414\/CNP63138"},{"key":"key\n\t\t\t\t20171012174017_BIB38","unstructured":"Graff L, Burnel D. Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol1995; 90: 389\u2013401"},{"key":"key\n\t\t\t\t20171012174017_BIB39","doi-asserted-by":"crossref","unstructured":"Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant2004; 19 [Suppl 1]: i19\u2013i24","DOI":"10.1093\/ndt\/gfh1004"},{"key":"key\n\t\t\t\t20171012174017_BIB40","doi-asserted-by":"crossref","unstructured":"Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract2006; 102: c61\u2013c71","DOI":"10.1159\/000088932"},{"key":"key\n\t\t\t\t20171012174017_BIB41","doi-asserted-by":"crossref","unstructured":"Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant1999; 14: 863\u2013867","DOI":"10.1093\/ndt\/14.4.863"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/8\/2065\/5153952\/gfl289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T04:47:10Z","timestamp":1555649230000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/8\/2065\/1820864\/Phosphate-binders-and-management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,9]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,6,9]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfl289","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,8]]},"published":{"date-parts":[[2006,6,9]]}}}